Beclomethasone dipropionate aerosol and oropharyngeal candidiasis.
In a survey of 400 consecutive patients with chronic asthma treated with beclomethasone dipropionate aerosol (up to 400 mug/day) the prevalence of oropharyngeal thrush was 4-5%. The prevalence of this complication was not significantly related to sex, age, duration of treatment with beclomethasone or concurrent treatment with prednisolone. Yeasts were isolated from throat swabs in about 60% of all patients and in 48% of normal controls. Thus, although a diagnosis of oropharyngeal thrush was recorded only when the presence of characteristic lesions in the pharynx was associated with a positive culture, there was a large number of patients and controls without thrush who harboured yeasts in the throat. One in 3 patients with thrush complained of sore throat or hoarseness, but 1 in 4 patients without thrush had similar symptoms. These findings suggest that, although treatment with beclomethasone dipoprionate aerosol undoubtedly can cause oropharyngeal thrush, this condition is not an inevitable result of colonization of the oropharynx by yeasts, nor is it necessarily associated with symptoms.
D000293:Adolescent; D000328:Adult; D000336:Aerosols; D000368:Aged; D001249:Asthma / Q000188:drug therapy; D001507:Beclomethasone / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002175:Candida / Q000302:isolation & purification; D002180:Candidiasis, Oral / Q000175:diagnosis / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000031:analogs & derivatives*; D008875:Middle Aged; D009055:Mouth / Q000382:microbiology; D010608:Pharyngeal Diseases / Q000175:diagnosis; D010614:Pharynx / Q000382:microbiology; D011239:Prednisolone / Q000627:therapeutic use
D000336:Aerosols; D011239:Prednisolone; D001507:Beclomethasone; D008775:Methylprednisolone